Genetic variants influencing SR B-ALL relapse risk identified
Genome and transcriptome sequencing revealed that subtypes such as TCF3/4::HLF were associated with an increased risk of relapse.
List view / Grid view
Genome and transcriptome sequencing revealed that subtypes such as TCF3/4::HLF were associated with an increased risk of relapse.
Four previously unknown genetic variants provide a new understanding of differences in risk between individuals of varying ancestries.
The combination therapy worked faster and was lessened the number of leukaemia cells compared to asparaginase or venetoclax alone.
A new proof-of-principle study demonstrates the DCAF5 protein is a promising target, which could avoid the need for toxic therapies.
New understanding of the CRC and its interaction with STAT3 could lead to novel therapeutics and combination strategies.
Researchers have created dual-targeted CARs, which performed better than single-targeted CARs in both in vivo and in vitro experiments.
RBM5 removal from cells meant that HOXA9 mRNA levels were greatly reduced, which could lead to therapies targeting HOXA9-driven leukaemia.
New research improves patient care by finding where gene copies integrate into DNA and using lentiviral vectors.
Researchers find genetic explanation for increased risk of developing second cancers.
St. Jude Children’s Research Hospital, in collaboration with ESR Limited, discovered that specific immune cells present in individuals months before a flu infection can better predict symptom development compared to current antibody-based methods.
Researchers provide new insights into viral evolution and have significant implications for understanding and predicting the behaviour of influenza and other mutating diseases.
US researchers developed a next-generation computational tool called NetBID2 that can uncover difficult-to-identify proteins that drive biological processes contributing to cancer.
St. Jude Children's Research Hospital, US, scientists created a new combination therapy method to tackle drug resistance in a type of leukaemia with KMT2A gene rearrangement.
Researchers have found that new sickle cell disease gene therapies depend on choosing the right laboratory mice.
The decreased expression of PTEN in mouse models was found to make rhabdomyosarcoma tumours more aggressive, highlighting new treatment approaches.